Yuanyi Biopharma Showcases Four Innovative Research Programs at SITC 2023, Highlighting Global Development Potential
Oricell Therapeutics
Developer of Tumor Immunocyte Products
Shanghai, China, November 3, 2023 — Oricell Therapeutics Holdings Limited at the 2023 Society for Immunotherapy of Cancer Annual Meeting（SITC 2023）The four research achievements have now been fully disclosed, covering the company's four clinical and preclinical projects, including a clinical-stage therapy for relapsed/refractory multiple myeloma.（R/R MM）GPRC5D-Targeted CAR-T Product（OriCAR-017）, two preclinical-stage CAR-T projects, respectively targeting advanced liver cancer: the GPC3-CAR-T project secreting CD3-AFP BiTE（OriCAR633）Project of MSLN-CAR-T Secreting PD-L1 Antibody for Gastric Cancer/Pancreatic Cancer（OriCAR627）, and a preclinical bispecific antibody project targeting the tumor microenvironment metabolism and immune checkpoint CD39/PD-L1.
Project:OriCAR-017
Title:Optimization of GPRC5D-targeted CAR T cells (OriCAR-017) for multiple myeloma
Abstract Number:326
Abstract Highlights:
• GPRC5D, a member of the G protein-coupled receptor family C group 5, is a novel target for the treatment of multiple myeloma. It is highly expressed in myeloma cells and hardly expressed in normal tissues. Moreover, GPRC5D is independently expressed with BCMA on CD138+ cells. Research data indicate that its upregulated expression correlates with poor prognosis in patients.
• Preclinical studies have shown that OriCAR-017 has high cell expansion potential, while demonstrating excellent cell lysis capability, with low toxicity and high anti-tumor activity.
• A Phase I Clinical Trial（POLARIS Study,Clinical Trial.gov : NCT05016778）Shows that the overall objective response rate of OriCAR-017 in treating R/R MM（ORR）At 100%, the sCR/CR remission rate was 80%, demonstrating significant safety advantages and indicating that OriCAR-017 has the potential to be the best in its class.
Project:OriCAR-017
Title:Optimization of GPRC5D-targeted CAR T cells (OriCAR-017) for multiple myeloma
Abstract Number:326
Summary Highlights:
• GPRC5D, a member of the G protein-coupled receptor family C group 5, is a novel target for multiple myeloma treatment. It is highly expressed in myeloma cells and is barely expressed in normal tissues. Moreover, GPRC5D is independently expressed with BCMA on CD138+ cells. Research data indicate that its upregulated expression correlates with poor patient prognosis.
• Preclinical studies have shown that OriCAR-017 has high cell expansion potential, while demonstrating excellent cell lysis capability, with low toxicity and high anti-tumor activity.
• A Phase I clinical trial (POLARIS Study, Clinical Trial.gov: NCT05016778) showed that OriCAR-017 achieved an overall objective response rate (ORR) of 100% and an sCR/CR rate of 80% in treating R/R MM, demonstrating significant safety advantages and indicating the potential for OriCAR-017 to become the best-in-class product.
Project:OriCAR627
Title:Empowering Cancer Immunotherapy by Mesothelin-Directed CAR T cells Engineered to secret Checkpoint Inhibitors
Abstract Number:333
Abstract Highlights:
• The anti-tumor efficacy of CAR-T cell therapy in solid tumors is often limited by immune escape mechanisms, including upregulated immune checkpoint molecules. Therefore, there is an urgent need to develop strategies that can address these immune escape mechanisms and enhance the therapeutic effects of CAR-T therapy in solid tumors.
• This study focuses on the company's independently developed MSLN CAR-T cell product.（OriCAR627）On the basis, a CAR-T cell product designed for secreting antibodies targeting immune checkpoints was developed.
• The CAR-T cell product secreting PD-L1 enhances in vivo anti-tumor efficacy, and the secretion of PD-L1 antibody increases over time after target antigen stimulation.
Project:OriA631-B
Title:OriA631-B: A First-in Class CD39/PD-L1 Bispecific Antibody Unleashing Enhanced Cancer Immunotherapy
Abstract Number:488
• CD39, as an immunometabolic checkpoint, is highly expressed in tumor cells and immune cells infiltrating the tumor microenvironment, such as T cells, NK cells, and myeloid cells. PD-L1, as an immune checkpoint, is mainly expressed on tumor cells. Both play important roles in immune tolerance and suppression.
• OriA631-B is a novel CD39/PD-L1 bispecific antibody independently developed by Qrigincell Therapeutics. While inhibiting the immunosuppressive functions of both targets, it can also act as an immune cell engager to exert enhanced tumor-killing effects. In preclinical studies, OriA631-B demonstrated significantly stronger in vivo anti-tumor activity compared to the combination therapy of CD39 monoclonal antibody and PD-L1 monoclonal antibody.
• Preclinical data suggest that OriA631-B has broad application prospects in the immunotherapy of tumors.
(Swipe up and down to view more)
Qrigincell Therapeutics, founded in 2015, is an innovative biopharmaceutical company at the clinical stage, developing tumor cell immunotherapy products based on its proprietary technology platform. With the mission of "developing accessible and effective drugs to address unmet clinical needs," Qrigincell Therapeutics has independently built the Ori®Ab、Ori®With multiple patented technology platforms such as CAR-T, the company has laid out over a hundred patents across more than 20 countries and regions worldwide. It possesses over 10 cell drug pipelines targeting cancer treatment, covering indications with broad therapeutic needs such as liver cancer, multiple myeloma, gastric cancer, pancreatic cancer, cholangiocarcinoma, ovarian cancer, and non-small cell lung cancer.
The exploratory clinical research data of Ori-C101, the first CAR-T cell product developed by the company targeting GPC-3 for the treatment of advanced liver cancer, was positively received at the 2021 ASCO Annual Meeting. A Phase I clinical study in China, led by Fudan University's Zhongshan Hospital and involving seven research centers, has been initiated. OriCAR-017, China’s first and the world’s second CAR-T product targeting GPRC5D for the treatment of relapsed and refractory multiple myeloma, obtained clinical approval from the NMPA and FDA Orphan Drug Designation. Its exploratory clinical research data was disclosed in oral presentations at the 2022 ASCO and 2022 EHA Annual Meetings, with follow-up data published in The Lancet Haematology. A Phase I clinical study in China, led by the First Affiliated Hospital of Zhejiang University School of Medicine, has been launched. The bispecific antibody drug YN051 targeting PD-L1/4-1BB was licensed to Antengene for a total deal value of $142 million.（B.6996）Continued development, currently conducting Phase I clinical trials in Australia, the United States, and China.
The company completed a Series B financing round with a total amount exceeding 120 million US dollars in 2022, and a 45 million US dollar Series B1 financing round in February 2023. In the future, it will continue to develop innovative cell immunotherapy drugs that are effective, differentiated, and cost-accessible, and accelerate the global development process of its core products.
●Share the vast new drug ecosystem resource library;
●Exclusive discount for Tongxiyi events;
●Membership-exclusive seating and expert exchange opportunities;
●Priority sponsorship rights for Tongxiyi events;
● Institutional brand activity planning and comprehensive promotion;
●One-on-one attentive service from the Secretariat.
